<?xml version="1.0" encoding="UTF-8"?>
<p id="Par5">Prior to the COVID-19 outbreak, the plan in South Africa was to phase out the old first-line fixed dose combination pill of tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TEE) slowly over 1–2 years. Since TEE stocks in the Western Cape are limited and TLD is plentiful, it is essential to roll-out TLD as planned [
 <xref ref-type="bibr" rid="CR7">7</xref>]. What’s more, TLD is a more effective ARV [
 <xref ref-type="bibr" rid="CR8">8</xref>, 
 <xref ref-type="bibr" rid="CR9">9</xref>]. During a highly infectious respiratory pandemic, PLHIV should be on the best ARV regimen available to minimize their risk of virologic failure, immunocompromise, and severe COVID-19 infection.
</p>
